Alzheimer Disease

In clinical trials, lecanemab showed a reduction of amyloid beta plaque in patients with Alzheimer disease.

Testosterone may protect the brain against dementia pathology, but the association has not been proven.

Infections were associated with a 1.49-fold increase in the rate of dementia in both the short- and long-term rates, however, the increases were greater in the short term.

Symptoms of dementia can be difficult to differentiate from typical age-related behavior changes and other common and potentially curable conditions.

One IVIG product showed overall improvement in neuroprotection, including alleviating cognitive decline and ameliorating AB deposition in Alzheimer disease.

Heart health may influence long-term brain health as early as middle age.

This social determinant of health could have the same level of negative impact on health as the experience of racism, poverty, or low education.

UB-311 has shown to be well-tolerated with a durable antibody response in a previous phase 1 trial, and new results from a phase 2a study support its continued development.

Through previous literature, investigators found that intervention with nutritional supplements may help to improve cognitive performance and reduce the severity of memory impairment in adults with Alzheimer disease.

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Pharmacists play a key role in the management of modern monoclonal antibody treatments for Alzheimer disease.

New anti-amyloid monoclonal antibody drugs for Alzheimer disease have produced encouraging results in targeting the accumulation of amyloid beta plaques; however, questions remain regarding the risk-benefit profile and cost implications.

The research narrows the most at-risk populations and how to mitigate the impacts on adults with ADRD.

Participants were able to stop treatment after achieving amyloid plaque clearance and experience lasting results.

Tooth loss and gum disease may play a role in the health of the brain area that controls thinking and memory.

Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.

To slow the production of MCI and dementia, utilizing more ways of establishing the diagnoses for women can prevent the progression.

Utilizing longitudinal assessments of language impairment and clinical progression could help identify challenges earlier.

Leqembi is an intravenous injection for the treatment of Alzheimer disease.

Brexpiprazole was associated with a statistically and clinically meaningful improvement in agitative behaviors caused by dementia compared to placebo.

Lack of awareness, or anosognosia, may be present up to 2 to 3 years before an Alzheimer dementia diagnosis is made.

More than half of patients with Alzheimer disease administered donanemab showed a significantly reduced cognitive and functional decline.

As more drugs gain coverage, decision-makers will need to more accurately diagnose Alzheimer disease, especially in the community setting.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Perceived stress and cognitive performance are independently associated. Stress can also increase the risk of worsening cognition.

Eli Lilly treatment targets soluble amyloid beta and did not clear plaque or halt accumulation of amyloid in individuals treated with the drug in the A4 study.

Investigators noted medication prescription disparities among patients with dementia despite factoring for age and sex.

Low cognitive functioning and cognitive decline have been linked to an increased risk of morbidity and mortality.

Promising results for lecanemab's efficacy in patients with mild cognitive impairment or mild dementia associated with Alzheimer disease were accompanied by reports of adverse effects associated with treatment.

The model can predict the chronological ages of cognitively normal participants with an average absolute error of 2.3 years, which is about 1 year more accurate than an existing model.